# Total colectomy for multiple metachronous colon cancers in a patient with Lynch syndrome

**Authors:** Masatoshi Kochi, Manabu Shimomura, Takao Hinoi, Hiroaki Niitsu, Takuya Yano, Shoichiro Mukai, Hiroyuki Sawada, Masashi Miguchi, Yasufumi Saito, Tomohiro Adachi, Yasuyo Ishizaki, Hiroyuki Egi, Hideki Ohdan

PMC · DOI: 10.1186/s40792-015-0081-x · Surgical Case Reports · 2015-09-09

## TL;DR

A 58-year-old man with Lynch syndrome underwent total colectomy for multiple colon cancers, highlighting the importance of this approach in managing the condition.

## Contribution

The case provides insights into the clinical management of multiple metachronous colorectal cancers in Lynch syndrome patients.

## Key findings

- Total colectomy was performed for advanced transverse colon cancer in a patient with Lynch syndrome.
- Histological findings confirmed mucinous adenocarcinoma with no lymph node metastasis and loss of MSH2 protein expression.
- The case supports the use of total colectomy in managing multiple metachronous colorectal cancers in LS patients.

## Abstract

Lynch syndrome (LS) is a disorder caused by mismatch repair gene mutations, which have been recognized to be associated with an increased frequency of colorectal and extracolorectal tumors. However, it remains controversial as to whether total or segmental colectomy should be performed to treat colorectal cancer in patients with LS. A 58-year-old male underwent total colectomy with ileostomy for advanced transverse colon cancer. He was also found to have LS based on his characteristic family history and the findings of a preoperative examination, including a microsatellite instability analysis of past multiple metachronous cancers. The postoperative histological findings showed mucinous adenocarcinoma without lymph node metastasis, and the loss of the MSH2 protein expression was confirmed on an immunohistochemical examination. The present case provided important information on the clinical management of multiple developing metachronous colorectal cancers in patients with LS.

## Linked entities

- **Proteins:** MSH2 (mutS homolog 2)
- **Diseases:** Lynch syndrome (MONDO:0005835), colorectal cancer (MONDO:0005575), mucinous adenocarcinoma (MONDO:0004957)

## Full-text entities

- **Genes:** MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}
- **Diseases:** lymph node metastasis (MESH:D008207), MS (MESH:D009103), MLPA (MESH:D019966), adenomatous polyp (MESH:D018256), depression (MESH:D003866), mucinous (MESH:D002288), adenomas (MESH:D000236), abdominal adhesion (MESH:D000007), lesion (MESH:D009059), MSH2 deficiency (MESH:D007153), LS (MESH:D003123), MK (MESH:D007706), CRC (MESH:D015179), transverse colon tumor (MESH:D003110), FAP (MESH:D011125), signet ring cell carcinoma (MESH:D018279), Cancer (MESH:D009369), metastasis (MESH:D009362), bladder/urinary tract cancer (MESH:D001749), adenocarcinoma (MESH:D000230), adenocarcinoma of the stomach (MESH:D013274), UC (MESH:D003093), MSI (MESH:D053842), colonic disease (MESH:D003108)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** GGC > AGC, p.G40S

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4564456/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4564456/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC4564456/full.md

---
Source: https://tomesphere.com/paper/PMC4564456